Claybrook Capital’s Bristol-Myers Squibb BMY Stock Holding History

Claybrook Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,220	Closed	-$1.84M	–	132
2022 Q1	$1.84M	Sell	25,220 -1,100	-4%	-$73.9K	0.91%	36
2021 Q4	$1.64M	Buy	+26,320	New	+$1.54M	0.77%	39
2021 Q3	–	Sell	-39,731	Closed	-$2.65M	–	141
2021 Q2	$2.65M	Buy	+39,731	New	+$2.59M	0.87%	35
2020 Q2	–	Sell	-25,639	Closed	-$1.43M	–	90
2020 Q1	$1.43M	Sell	25,639 -1,151	-4%	-$70.4K	1.3%	28
2019 Q4	$1.76M	Hold	26,790	–	–	0.82%	46
2019 Q3	$1.36M	Buy	26,790 +1,000	+4%	+$47K	0.7%	51
2019 Q2	$1.17M	Buy	25,790 +2,200	+9%	+$102K	0.61%	54
2019 Q1	$1.13M	Buy	23,590 +23,006	+3,939%	+$1.15M	0.59%	55
2018 Q4	$30K	Sell	584 -6	-1%	-$322	0.01%	303
2018 Q3	$37K	Hold	590	–	–	0.02%	119
2018 Q2	$33K	Hold	590	–	–	0.02%	121
2018 Q1	$37K	Sell	590 -4,681	-89%	-$301K	0.02%	115
2017 Q4	$323K	Buy	+5,271	New	+$330K	0.23%	67

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Claybrook Capital's BMY Position: Q2 2022 in Review

Claybrook Capital sold out of Bristol-Myers Squibb (BMY) in Q2 2022, closing a stake of 25,220 shares — an estimated $1.84M sold.

Claybrook Capital first reported a position in BMY in Q4 2017 and held it in 13 quarters. The position peaked at $2.65M in Q2 2021. 2,538 funds tracked by Wall St. Rank hold BMY as of Q2 2022.

Claybrook Capital reported no remaining Bristol-Myers Squibb position as of Q2 2022 after selling out during the quarter.
Claybrook Capital sold 25,220 Bristol-Myers Squibb shares in Q2 2022, an estimated $1.84M.
Claybrook Capital first reported a position in Bristol-Myers Squibb in Q4 2017 and held it in 13 quarters.
Claybrook Capital's Bristol-Myers Squibb position peaked at $2.65M in Q2 2021.
2,538 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2022.

Based on Claybrook Capital's 13F filing for Q2 2022, filed 18 Jul 2022.